RXi Pharmaceuticals Corporation (RXII)

1.53 +0.01 (+0.658%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.52

Price Open 1.51

Volume: 31,770

Avg Volume: 613,176

Market Cap: 6.7M

P/E Ratio -0.46

52 Wk Range 1.29-7.7



RXII Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
3.05M
464,135
2.81
15.24%

2018-07-13
3.05M
491,431
3.63
16.14%

2018-06-29
3.05M
428,934
5.39
14.09%

2018-06-15
3.05M
426,246
2.11
14.00%




RXII Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-10
Q1 2018
N/A
0.00 (0)
-0.90
0.00

2018-03-29
Q4 2017
N/A
0.00 (0)
-0.90
0.00

2018-03-26
Q4 2017
AMC
-0.96 (1)
-0.90
0.00

2017-11-08
Q3 2017
AMC
-0.11 (1)
-0.90
0.00

News

RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors (2018-08-15 09:25 PR Newswire)

MARLBOROUGH, Mass. , Aug. 15, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform today announced that…

 

RXI Pharmaceuticals Corporation (RXII) CEO Geert Cauwenbergh on Q2 2018 Results - Earnings Call Transcript (2018-08-14 22:48 SeekingAlpha)

RXI Pharmaceuticals Corporation (RXII) Q2 2018 Earnings Conference Call August 14, 2018 4:30 PM ET Executives Tamara McGrillen - Head of Investor Relations Geert Cauwenbergh - President and Chief Executive Officer Caitlin Kontulis - Principal Accounting Officer Gerrit Dispersyn…

 


Statistics

Shares Outstanding: 4.38M

Top 15 Institution Percent: 54.50

Price To Sales: 69.29

Price To Book: 2.05

Revenue: N/A

Gross Profit: N/A

Cash: 5.42M

Debt: N/A

Return On Assets: -119.51

Return On Equity: -187.16

Profit Margin: N/A

Price History

Beta: 1.80

50-day Moving Avg: 1.89

200-day Moving Avg: 3.50

YTD Change: -72.18

5-day Change: -8.93

1-month Change: -18.62

3-month Change: -35.40

6-month Change: -56.03

1-year Change: -74.29

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: RXi Pharmaceuticals Corporation

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.rxipharma.com

RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.